# Evidence Quality Assessment - Complete Analysis
## 15 Competency Questions Validation Round (2026-02-01)

---

## Key Metrics at a Glance

| Metric | Value | Interpretation |
|--------|-------|-----------------|
| **Total CQs Assessed** | 15 | Complete validation suite |
| **Total CURIEs Identified** | 110 | Strong entity resolution |
| **Avg CURIEs per CQ** | 7.3 | Adequate entity coverage |
| **Avg API Tools per CQ** | 5.3 | Diverse data sources |
| **Avg Confidence Scores** | 1.8 | ~47% have quantified metrics |
| **HIGH Quality CQs** | 7 (46.7%) | Excellent evidence base |
| **MEDIUM Quality CQs** | 7 (46.7%) | Adequate but improvable |
| **LOW Quality CQs** | 1 (6.7%) | Requires remediation |

---

## Evidence Quality Scorecard (Ranked by Quality)

### üåü HIGH Quality (7 CQs)
Robust evidence with multiple API tools and/or quantified confidence scores

| Rank | CQ | Title | CURIEs | Tools | Scores | Key Strength |
|------|-----|-------|--------|-------|--------|--------------|
| 1 | **CQ-3** | Alzheimer's Gene-Protein Network | 11 ‚≠ê | 5 | 7 ‚≠ê‚≠ê | Multiple interaction metrics |
| 2 | **CQ-6** | BRCA1 Regulatory Network | 9 | 5 | 6 ‚≠ê‚≠ê | Complete regulatory map |
| 3 | **CQ-10** | Huntington's Disease Novel Targets | 6 | 6 | 5 ‚≠ê | Rich STRING interactions |
| 4 | **CQ-1** | Palovarotene Mechanism for FOP | 4 | 7 ‚≠ê | 2 | Multi-API validation |
| 5 | **CQ-11** | p53-MDM2-Nutlin Axis | 6 | 7 ‚≠ê | 3 | Therapeutic axis validated |
| 6 | **CQ-5** | MAPK Regulatory Cascade | 8 | 5 | 2 | Canonical pathway |
| 7 | **CQ-7** | NGLY1 Deficiency Drug Repurposing | 6 | 7 ‚≠ê | 2 | Complex interactions |

### ‚ö†Ô∏è MEDIUM Quality (7 CQs)
Adequate evidence but lacking either quantified scores or API tool diversity

| CQ | Title | CURIEs | Tools | Scores | Gap |
|----|-------|--------|-------|--------|-----|
| CQ-2 | FOP Drug Repurposing | 9 ‚≠ê | 7 ‚≠ê | 0 | No interaction validation |
| CQ-4 | Alzheimer's Therapeutics | 10 ‚≠ê | 6 | 0 | No confidence metrics |
| CQ-8 | ARID1A Synthetic Lethality | 10 ‚≠ê | 7 ‚≠ê | 0 | Synthetic lethal unquantified |
| CQ-9 | Dasatinib Safety Profile | 6 | 5 | 0 | Off-target effects unvalidated |
| CQ-13 | Commercialization Phase 3 Trials | 5 | 3 | 0 | Limited API coverage |
| CQ-14 | Feng Synthetic Lethality | 4 | 5 | 0 | Partial validation (API key needed) |
| CQ-15 | CAR-T Regulatory Landscape | 5 | 4 | 0 | Trial landscape only |

### ‚ùå LOW Quality (1 CQ)
Insufficient API tool diversity - single endpoint reliance

| CQ | Title | Issue | Recommendation |
|----|-------|-------|-----------------|
| **CQ-12** | Health Emergencies Clinical Trial Landscape | Uses only ClinicalTrials.gov (1 API) | Add MONDO, ChEMBL, HGNC grounding |

---

## API Tool Distribution

### Top 10 Most-Used Tools (Across 15 CQs)
```
1. hgnc_search_genes              [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 13 CQs (86.7%)
2. hgnc_get_gene                  [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 12 CQs (80.0%)
3. chembl_search_compounds        [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 10 CQs (66.7%)
4. chembl_get_compound            [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 10 CQs (66.7%)
5. string_search_proteins         [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 7 CQs (46.7%)
6. string_get_interactions        [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 7 CQs (46.7%)
7. curl(ClinicalTrials.gov)       [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 6 CQs (40.0%)
8. opentargets_get_associations   [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 4 CQs (26.7%)
9. curl(ChEMBL API)               [‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà] 4 CQs (26.7%)
10. wikipathways_*                [‚ñà‚ñà‚ñà‚ñà] 2 CQs (13.3%)
```

### API Ecosystem Health

| API | Critical? | Coverage | Trend |
|-----|-----------|----------|-------|
| **HGNC** | ‚úÖ YES | 86.7% | Core (gene foundation) |
| **ChEMBL** | ‚úÖ YES | 66.7% | Core (drug foundation) |
| **STRING** | ‚ö†Ô∏è PARTIAL | 46.7% | Growing (interaction confidence) |
| **Open Targets** | ‚ö†Ô∏è PARTIAL | 26.7% | Underutilized |
| **ClinicalTrials.gov** | ‚ö†Ô∏è PARTIAL | 40.0% | Increasing (trial evidence) |
| **WikiPathways** | ‚ùå NO | 13.3% | **Severely underutilized** |

---

## CURIE Type Breakdown

### Distribution (110 Total Identifiers)
```
Type        Count   % of Total   Example
=========   =====   =========    =====================================
HGNC        65      59.1%        HGNC:11998 (TP53), HGNC:620 (APP)
ChEMBL      21      19.1%        CHEMBL:2105648 (Palovarotene)
NCT         15      13.6%        NCT:06463861 (CAR-T trial)
MONDO       4       3.6%         MONDO:0004975 (Alzheimer disease)
WikiPath    3       2.7%         WP:WP2760 (BMP pathway)
UniProt     2       1.8%         UniProt:P04637 (TP53 protein)
```

### Quality Implications
- **Strength**: Gene-centric design (59%) fits mechanistic questions
- **Weakness**: Only 3.6% MONDO disease references (opportunity gap)
- **Opportunity**: 2.7% pathway identifiers underexploited

---

## Confidence Score Analysis

### Availability by CQ Type

| CQ Type | CQs | With Scores | % with Scores | Median Score |
|---------|-----|-------------|---------------|--------------|
| **Gene Networks** | 4 | 4 | 100% | 0.99 |
| **Drug Mechanism** | 1 | 1 | 100% | 0.53 |
| **Pathways** | 2 | 1 | 50% | 0.999 |
| **Drug Repurposing** | 4 | 0 | 0% | N/A |
| **Therapeutics** | 2 | 0 | 0% | N/A |
| **Clinical Trials** | 2 | 0 | 0% | N/A |

### Key Insight
- **Protein-level** evidence (STRING) provides quantified scores
- **Drug repurposing** and **clinical trial** domains lack numerical metrics
- **Score range**: 0.435 (Dasatinib) to 0.999 (multiple interactions)

---

## Exemplary vs. Problematic Evidence Patterns

### ‚úÖ Exemplary (CQ-3: Alzheimer's Gene Network)
```
Evidence Trail:
‚îú‚îÄ‚îÄ Entity Resolution (11 HGNC genes)
‚îú‚îÄ‚îÄ STRING Validation (7 interaction scores: 0.956-0.999)
‚îú‚îÄ‚îÄ Disease Association (Open Targets: 0.786)
‚îú‚îÄ‚îÄ Cross-References (Ensembl, UniProt, chromosomal location)
‚îî‚îÄ‚îÄ Reproducibility: Excellent (public APIs, no auth)
```

### ‚ö†Ô∏è Problematic (CQ-12: Health Emergencies)
```
Evidence Trail:
‚îú‚îÄ‚îÄ Trial Identification (11 NCT IDs)
‚îú‚îÄ‚îÄ ‚ùå NO Disease Formalization (MONDO)
‚îú‚îÄ‚îÄ ‚ùå NO Compound Mapping (ChEMBL)
‚îú‚îÄ‚îÄ ‚ùå NO Gene Target Resolution (HGNC)
‚îú‚îÄ‚îÄ ‚ùå NO Cross-Validation
‚îî‚îÄ‚îÄ Remediation: 4 additional APIs needed
```

---

## Actionable Recommendations

### üî¥ URGENT (1-2 weeks)
**Remediate CQ-12**
1. Map each clinical trial condition ‚Üí MONDO identifier
2. Extract trial interventions ‚Üí Map to ChEMBL compounds
3. Identify target genes ‚Üí HGNC identifiers
4. Result: 1 API ‚Üí 4-5 APIs, +8-10 CURIEs, move to MEDIUM quality

### üü° SHORT-TERM (2-4 weeks)
**Enhance Drug Repurposing Evidence**
1. Add STRING validation to CQ-2, CQ-4, CQ-8, CQ-9
2. Expand Open Targets coverage (currently 26.7%)
3. Quantify synthetic lethality confidence in CQ-8, CQ-14
4. Result: 0 scores ‚Üí 3-5 scores per CQ, move to HIGH

### üü¢ MEDIUM-TERM (1 month)
**Broaden Pathway Integration**
1. Apply WikiPathways to CQ-3, CQ-4, CQ-6, CQ-10
2. Formalize all disease terms as MONDO identifiers (+15-20 CURIEs)
3. Cross-validate pathway components via interaction data
4. Result: Complete mechanistic coverage

---

## Overall Assessment

| Dimension | Status | Evidence |
|-----------|--------|----------|
| **Entity Resolution** | ‚úÖ STRONG | 7.3 avg CURIEs, 110 total identifiers |
| **API Diversity** | ‚úÖ GOOD | 5.3 avg tools, HGNC+ChEMBL+STRING core |
| **Confidence Quantification** | ‚ö†Ô∏è PARTIAL | 47% of CQs lack numerical metrics |
| **Clinical Integration** | ‚ö†Ô∏è PARTIAL | 40% of CQs, mostly decontextualized |
| **Pathway Grounding** | ‚ùå WEAK | Only 13% pathway coverage |
| **Disease Formalization** | ‚ùå WEAK | 3.6% MONDO references |

### Final Verdict
**VALID WITH RECOMMENDATIONS** - 93.3% of CQs meet MEDIUM+ quality. Evidence base is comprehensive, well-distributed, and reproducible. Improvements focus on scoring diversity and clinical contextualization, not fundamental data gaps.

---

## Detailed Findings

### CQ-by-CQ Evidence Trails

See **EVIDENCE_QUALITY_REPORT.md** for comprehensive analysis of:
- Provenance strength assessment for all 15 CQs
- Cross-question patterns and API ecosystem health
- Specific recommendations for each MEDIUM-quality CQ
- Validation gaps and remediation strategies

### Machine-Readable Data

See **evidence_quality_scorecard.csv** for:
- Complete CQ metadata (title, domain, dates)
- Quantified metrics (CURIEs, API tools, scores)
- API tool lists and CURIE type breakdown
- Quality ratings and primary domains

---

## Reference Documents
- **EVIDENCE_QUALITY_REPORT.md** - Comprehensive 16KB analysis report
- **evidence_quality_scorecard.csv** - Machine-readable data export
- **ASSESSMENT_SUMMARY.md** - This executive overview

